Arterial Chemotherapy for Colorectal Cancer Metastases in the Liver: Technical Aspects and Oncological Feasibility

L.O. Polischuk, O.G. Skipenko

Abstract


Colorectal cancer is still the leader in terms of cancer incidence and mortality in most countries of the world. The main indicator of fatal progression of this disease — the active growth of hematogenous metastasis. Liver — the first organ on the way to the spread of tumor cells, and the most frequent location of synchronous and metachronous secondary lesions. The unique anatomical features of the tumor blood supply have allowed researchers to modify the standard methods of delivery of cytotoxic drugs, replacing the systemic administration by intra-arterial intrahepatic infusion. The main advantage of this technique — possibility of regional administration of the drug directly to the tumor deposits in the liver, which, theoretically, should increase the efficiency of chemotherapy at relatively low rates of systemic toxicity. However, oncologic indices of intra-arterial infusion efficacy remain controversial. In our review, we examined the technical aspects and specific complications associated with regional chemotherapy, as well as the long-term results, including in comparison with traditional schemes of cytostatic therapy.


References


Perfusion of colorectal hepatic metastases. Relative distribution of flow from the hepatic artery and portal vein / Ridge J.A., Bading J.R., Gelbard A.S. et al. // Cancer. — 1987. — № 59. — Р. 1547-1553.

Folkman J. The role of angiogenesis in tumor growth / Folkman J. // Semin. Cancer Biol. — 1992. — № 3. — Р. 65-71.

Combined regional and systemic chemotherapy by a mini-invasive approach for the treatment of colorectal liver metastases / Zanon C., Grosso M., Clara R. et al. // Am. J. Clin. Oncol. — 2001. — № 24. — Р. 354-359.

Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy / Tanaka T., Arai Y., Inaba Y. et al. // J. Vasc. Interv. Radiol. — 2003. — № 14. — Р. 63-68.

Catheter redundancy in the aortic arch increases the risk of stroke in left subclavian arterial port-catheter systems / Hirota T., Yamagami T., Tanaka O. et al. // J. Vasc. Interv. Radiol. — 2005. — № 16. — Р. 471-476.

De Baere T. Arterial therapies of colorectal cancer meta­stases to the liver / de Baere T., Deschamps F. // Abdom. Imaging. — 2011. — № 36. — Р. 661-670.

Wickremesekera J.K. Hepatic artery access ports: reco­gnizing and avoiding the problems / Wickremesekera J.K., Cannan R.J., Stubbs R.S. // Aust. N. Z. J. Surg. — 2000. — № 70. — Р. 496-502.

Seki H. Side-Hole catheter placement for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer: long-term treatment and survival benefit / Seki H., Ozaki T., Shiina M. // AJR. — 2008. — № 190. — Р. 111-120.

Skitzki J.J. Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials / Skitzki J.J., Chang A.E. // Surg. Oncol. — 2002. — № 11. — Р. 123-135.

Percutaneous femoral implantation of an arterial port ca­the­ter for intraarterial chemotherapy: feasibility and predictive factors of long-term functionality / Deschamps F., Rao P., Teriitehau Ch. et al. // J. Vasc. Interv. Radiol. — 2010. — № 21. — Р. 1681-1688.

Barnett K. Complications of hepatic artery infusion. A review of 4580 reported cases / Barnett K., Malafa M. // Int. J. Gastrointest. Cancer. — 2001. — № 30. — Р. 147-160.

Kemeny N. Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma / Kemeny N., Fata F. // J. Hepatobiliary Pancreat. Surg. — 1999. — № 1. — Р. 39-49.

Intrahepatic or systemic infusion of fluorodeoxyuridine in patiens with liner metastases from colorectal carcinoma / Kemeny N., Daly J., Reichman B. et al. // Ann. Int. Med. — 1987. — № 107. — Р. 459-465.

Biliary Sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors / Ito K., Ito H., Kemeny N. et al. // Ann. Surg. Oncol. — 2012. — № 19. — Р. 1609-1617.

Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Fede­ration Nationale des Centres de Lutte Contre le Cancer / Ducreux M., Ychou M., Laplanche A. et al. // J. Clin. Oncol. — 2005. — № 23. — Р. 4881-4887.

Sullivan R.D. Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion / Sullivan R.D., Norcross J.W., Watkins E. // N. Engl. J. Med. — 1964. — № 270. — Р. 321-327.

Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer / Patt Y., Boddie A., Charnsangavej C. et al. // J. Clin. Oncol. — 1986. — № 4. — Р. 1356-1364.

High-dose leucovorin and 5-fluorouracil bolus and infusion in advanced colorectal cancer / De Gramont A., Krulik M., Cady J. et al. // Eur. J. Clin. Oncol. — 1988. — № 24. — Р. 1499-503.

O’Neil B. Chemotherapy for advanced colorectal cancer: let’s not forget how we got here (until we really can) / O’Neil B., Goldberg R. // Semin. Oncol. — 2005. — № 32. — Р. 35-42.

Mocellin S. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer / Mocellin S., Pasquali S., Nitti D. // Cochrane Database of Systematic Reviews. — 2009. — Issue 3. — Р. 1-32.

Wolpin B. Systemic Treatment of Colorectal Cancer / Wolpin B., Mayer R. // Gastroenterology. — 2008. — № 134(5). — Р. 1296-1310.

Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases / Goere D., Deshaies I., de Baere T. et al. // Ann. Surg. — 2010. — № 251. — Р. 686-691.

Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure / Boige V., Malka D., Elias D. et al. // Ann. Surg. Oncol. — 2007. — № 15. — Р. 219-226.

Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? / Brouquet A., Overman M., Kopetz S. et al. // Cancer. — 2011. — № 117. — Р. 4484-4492.

Kanat O. What is the potential role of hepatic arterial infusion chemotherapy in current armamentorium against colorectal cancer / Kanat O., Gewirtz A., Kemeny N. // J. Gastrointest. Oncol. — 2012. — № 3(2). — Р. 130-138.

Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of Liver Metastases) group. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus / Adam R., De Gramont A., Figueras J. et al. // Oncologist. — 2012. — № 17(10). — Р. 1225-1239.

Palliative treatment of unresectable metastatic colorectal cancer / Fornaro L., Masi G., Loupakis F. et al. // Expert Opin. Pharmacother. — 2010. — № 11. — Р. 63-77.

Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): Results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial / Langer B., Bleiberg H., Labianca R. et al. // Proc. Amer. Soc. Clin. Oncol. — 2002. — № 21. — Р. 149a.

Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial / Portier G., Elias D., Bouche O. et al. // J. Clin. Oncol. — 2006. — № 24. — Р. 4976-4982.

Nelson R. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver / Nelson R., Freels S. // Cochrane Database Syst. Rev. — 2009. — № 4. — CD003770.

Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence. A comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy / Goere D., Benhaim L., Bonnet S. et al. // Ann. Surg. — 2013. — № 257. — Р. 114-120.

Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases / Sperling J., Schäfer T., Ziemann C. et al. // Clin. Exp. Metastasis. — 2012. — № 29(2). — Р. 91-99.

Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliolatin significantly reduces growth of CC531 colorectal rat liver metastases / Sperling J., Schäfer T., Ziemann C. et al. // Int. J. Colorectal Dis. — 2012. — acc. 15 dec. (Epub ahead of print).




DOI: https://doi.org/10.22141/1997-2938.3.22.2013.87434

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 UKRAINIAN JOURNAL OF SURGERY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru